Absolutely. Same point for $AMRN as for $NVS Entresto. By using the “wrong” comparitor, they generate positive data but leave unanswered questionshttps://twitter.com/Adrian_H/status/1062473481860931584 …
-
-
Replying to @sciencescanner @matthewherper
I'm also interested in the cost-effectiveness, based on the cost of Vascepa and the NNT (21 events prevented/5 patient-years) it looks like ~$315,000 per averted event even if the mineral oil didn't skew the results
1 reply 0 retweets 0 likes -
63,000 per event prevented.
1 reply 0 retweets 0 likes -
How so? By my calculations, based on a 5-year NNT of 21, and a monthly cost of $250 (averaged from a few online stores) for the 4g daily dose cited in the study, it would be 12*250*5*21 = $315,000 My cost for Vascepa could, of course, be incorrect, is it cheaper?
1 reply 0 retweets 0 likes -
It is my understanding It's not a 5 year calculation, the NNT calculation is an annual amount.
1 reply 0 retweets 0 likes -
Unless I'm wildly misreading the study, the NNT was based on a 5% absolute reduction over the course of the 5 years, and was not annualizedpic.twitter.com/Y9xuywcKvN
1 reply 0 retweets 0 likes -
Ok on the five year. On another note, the amount per script might be closer to gross revenue than net revenue. After insurance discounts, I would say closer to $210.
1 reply 0 retweets 0 likes -
Fair enough. That puts the cost per averted event at ~$260,000, which is still around 2.5x the willingness to pay threshold
1 reply 0 retweets 0 likes -
It's late, but isn't willingness to pay an annual amount?
1 reply 0 retweets 0 likes
Mmmm but the cost to prevent an event is fixed, it doesn't need annualization. If you gave Vascepa to 105 people, you'd expect 5 events prevented over 5 years at a cost of $315,000 per event, or 1 event prevented over 1 year for the same cost
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.